Dolutegravir: Clinical and laboratory safety in integrase inhibitor-naive patients

HIV Clinical Trials

Volumn 15, Issue 5, 2014, Pages 199-208

  Curtis, L ^a   Nichols, G ^b   Stainsby, C ^a   Lim, J ^a   Aylott, A ^a   Wynne, B ^b   Clark, A ^c   Bloch, M ^e   Maechler, G ^c   Martin Carpenter, L ^d   Raffi, F ^f   Min, S ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c VIIV HEALTHCARE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e Holdsworth House Medical Practice   (Australia)

^f NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Dolutegravir; HIV 1; Integrase inhibitor; Safety

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CREATININE; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; RALTEGRAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FUSED HETEROCYCLIC RINGS; LIPID;

ANTIVIRAL THERAPY; ARTICLE; CREATININE CLEARANCE; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTRANSAMINASEMIA; INSOMNIA; INTENTION TO TREAT ANALYSIS; KIDNEY FUNCTION; LIPID ANALYSIS; MENTAL DISEASE; META ANALYSIS; MIXED INFECTION; NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); BLOOD; CHEMICALLY INDUCED; HIV INFECTIONS; PSYCHOSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TOXIC HEPATITIS;

ANTI-HIV AGENTS; CREATINE KINASE; DRUG-INDUCED LIVER INJURY; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HUMANS; LIPIDS; PSYCHOSES, SUBSTANCE-INDUCED; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84922217238     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1505-199     Document Type: Article

References (13)

1. Stellbrink H-J, Reynes J, Lazzarin A, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS. 2013;27:1771-1778.
2. Raffi F, Rachlis A, Stellbrink H-J, et al; for the SPRING-2 Study Group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735-743.
3. Walmsley SL, Antela A, Clumeck N, et al; for the SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807-1818.
4. Clotet B, Feinberg J, van Lunzen J, et al, on behalf of the ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383:2222-2231.
5. Cahn P, Pozniak AL, Mingrone H, et al; for the extended SAILING Study Team. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382:700-708.
6. Epzicom [package insert]. Research Triangle Park, NC: ViiV Healthcare; 2012.
7. Isentress [package insert]. Whitehouse Station, NJ: Merck & Co Inc; 2012.
8. Kastrup J, Petersen P, Bartram R, Hansen JM. The effect of trimethoprim on serum creatinine. Br J Urol. 1985;57:265-268.
9. Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol. 2013;75:990-996.
10. st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2011; Denver, CO.
11. th International Workshop on Clinical Pharmacology of HIV Therapy; April 2012; Barcelona, Spain.
12. Song I, Min SS, Borland J, et al. Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects. J Acquir Immune Defic Syndr. 2010;55:365-367.
13. th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 2013; Kuala Lumpur, Malaysia.